Ali Khojasteh

Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

Gerald Batist, Gopal Ramakrishnan, Chandra Sekhar Rao et al. · Journal of Clinical Oncology · 2001 · 661 citations

Medicine, Oncology, Pharmacology +17

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist

Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla et al. · New England Journal of Medicine · 1999 · 371 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

John D. Hainsworth, W. Henwood Harvey, Kelly Pendergrass et al. · Journal of Clinical Oncology · 1991 · 154 citations

Medicine, Pharmacology, Pharmacotherapy +17